Jean-François Formela is a partner and focuses on novel drug discovery approaches and therapeutics. He joined Atlas Venture in 1993 to build the U.S. life sciences franchise.

He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA), and Korro Bio. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics.

His prior investments include Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL, acquired by Merck), Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL), Horizon Therapeutics (NASDAQ: HZNP), NxStage (NASDAQ: NXTM, acquired by Fresenius), and Translate Bio (NASDAQ: TBIO, acquired by Sanofi).

Jean-François is a member of the Mass General Brigham Innovation Advisory Board and a former trustee of the Boston Institute of Contemporary Art. He received his MD from Paris University School of Medicine and his MBA from Columbia University.